Genzyme has entered into an agreement with Bayer HealthCare to acquire worldwide rights to Campath for the development and commercialization for the treatment of multiple sclerosis (MS). Bayer will continue to fund a portion of Campath’s development in MS and will retain an option to co-promote the product if approved. Genzyme will assume sole responsibility for worldwide sales and marketing for Campath in B-cell chronic lymphocytic leukemia (CLL). Bayer will retain the right to develop and comm...